hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06305299 id: LCCC2152-ATL briefTitle: Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-03 date: 2026-03 date: 2024-03-12 date: 2024-04-23 name: UNC Lineberger Comprehensive Cancer Center class: OTHER briefSummary: The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. The study team wants to know how much (dose) of the iC9-CAR.B7-H3 T cells are safe to use in patients without causing too many side effects and what is the maximum dose could be tolerated.
There are two parts to this study. In part 1, approximately blood will be collected from subjects to prepare the iC9.CAR.B7-H3 T cells. The study team will collect disease-fighting T cells from the blood and modify them to prepare the iC9.CAR.B7-H3 T cells. In part 2, the iC9.CAR.B7-H3 T cells will be given to eligible subjects by infusion three days after completion of lymphodepletion chemotherapy. conditions: Ovary Neoplasm conditions: Ovarian Cancer conditions: Epithelial Ovarian Cancer conditions: Recurrent studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 27 type: ESTIMATED name: iC9-CAR.B7-H3 T cells name: Cyclophosphamide name: Fludarabine measure: Toxicity: NCI-CTCAE measure: Toxicity: Cytokine Release Syndrome (CRS) measure: Toxicity: Immune effector cell-associated neurotoxicity syndrome (ICANS) measure: The recommended phase 2 dose (RP2D) measure: Progression Free Survival (PFS) measure: Overall Survival (OS) measure: The disease control rate (DCR) sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lineberger Comprehensive Cancer Center city: Chapel Hill state: North Carolina zip: 27599 country: United States name: Caroline Babinec role: CONTACT email: Caroline_babinec@med.unc.edu name: Linda Van Le role: PRINCIPAL_INVESTIGATOR lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06305286 id: IRB23-1367 briefTitle: Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D) overallStatus: RECRUITING date: 2024-03-04 date: 2029-03 date: 2029-03 date: 2024-03-12 date: 2024-03-27 name: University of Chicago class: OTHER name: Juvenile Diabetes Research Foundation name: Cure Alliance briefSummary: AT-1501 is a monoclonal antibody. Antibodies are Y-shaped proteins that are produced naturally by the subject's immune system to attack and fight foreign substances that cause illness. Monoclonal antibodies are man-made proteins manufactured to serve as substitute antibodies to fight diseases. Monoclonal antibodies can restore, enhance, or mimic (copy) the immune system's attack process; they can also tone down the immune system. AT-1501 is thought to work by dampening down the immune system so that it will be less likely to attack the transplanted cells. For other types of transplants, like kidney, a drug called a calcineurin inhibitor is usually used to prevent rejection. That class of drugs can be toxic to islet cells. AT-1501 is an experimental agent that is anticipated to prevent rejection without harming the islet cells. conditions: Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 3 type: ESTIMATED name: AT-1501 measure: Number of Participants who are insulin-independent post- first and final transplant measure: Number of Participants with glycosylated hemoglobin (HbA1c) <7.0% measure: Number of Participants with free of serious hypoglycemic events (SHEs) post-first and final transplant measure: Number of Participants with HbA1c ≤6.5% AND free from SHEs post-first and final transplant. measure: Number of Participants with graft failure post final transplant. measure: Number of participants with impaired awareness of hypoglycemia after final islet cell transplant and after discontinuation of AT-1501. measure: Change in glycemic lability after final islet cell transplant and years after discontinuation of AT-1501 measure: Change in albumin excretion ratio (AER) post-first and final transplant. measure: Change in estimated glomerular filtration rate (eGFR) post-first and final transplant. measure: Change in percent new macroalbuminuria post-first and final transplant. measure: Change in variability after final islet cell transplant and years after discontinuation of AT-1501 sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Chicago status: RECRUITING city: Chicago state: Illinois zip: 60637 country: United States name: Piotr Witkowski, MD PhD role: CONTACT phone: 773-702-2447 email: pwitkowski@surgery.bs.uchicago.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06305273 id: 23-0150-A briefTitle: Effectiveness of Two Different Body Positions During Facemask Ventilation in Obese Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-25 date: 2025-03-01 date: 2025-03-01 date: 2024-03-12 date: 2024-03-20 name: Mount Sinai Hospital, Canada class: OTHER briefSummary: It is important to provide enough oxygen to the patients who are asleep during surgery. One way to do this is by using a mask placed over the face to help them breathe. When it becomes difficult getting enough oxygen into the patient's body using the mask, it's called difficult mask ventilation. There can be different reasons for this, and having a higher BMI is one of them. Body physique is assessed by Body Mass Index (BMI). This calculation gives an indication of a person's weight relative to their height.
There is some evidence in the research literature to suggest that when the patient is positioned in a way that helps their airway, like using a device to lift their head and torso 25 degrees , it might help the process of getting enough oxygen work better. The study aims to determine if patients with high BMI can breathe better using a face mask while they are in a head elevated position compared to lying flat on their back. conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This study is a prospective randomized cross-over trial to be conducted at Mount Sinai Hospital (Toronto, Ontario, Canada). primaryPurpose: PREVENTION masking: NONE count: 38 type: ESTIMATED name: Head position for face mask ventilation during induction supine name: Head position for face mask ventilation during induction head elevated measure: Average tidal volume measure: Predictors for difficult mask ventilation like BMI measure: Predictors for difficult mask ventilation like presence of beard measure: Predictors for difficult mask ventilation like Mallampati classification III or IV measure: Predictors for difficult mask ventilation like age of 57 yo or older. measure: Predictors for difficult mask ventilation like severely limited mandibular protrusion measure: Predictors for difficult mask ventilation like history of snoring. measure: Oropharyngeal airway measure: Insufficient mask ventilation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06305260 id: STUDY00000324 briefTitle: LOTUS Trial: Lumbar Ultrasound in Obstetric Patients With BMI > 40 acronym: LOTUS overallStatus: ENROLLING_BY_INVITATION date: 2023-11-01 date: 2024-12-30 date: 2024-12-30 date: 2024-03-12 date: 2024-03-20 name: MetroHealth Medical Center class: OTHER briefSummary: The goal of this clinical trial is to compare traditional palpation to pre-procedural lumbar ultrasound prior to epidural placement in obese (BMI \>40) obstetric patient population. The main questions it aims to answer are:
* Is there no difference in time to epidural loss between pre-procedural lumbar ultrasound and traditional palpation during epidural placement? Participants will be randomized to either a pre-procedural lumbar ultrasound or traditional palpation at the time of epidural placement. conditions: Obesity, Morbid conditions: Labor Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 150 type: ESTIMATED name: Lumbar Ultrasound measure: Epidural Redirects measure: Total time to epidural space measure: Number of attempts at a different level measure: Epidural replacement rate measure: Patient satisfaction sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MetroHealth Hospital city: Cleveland state: Ohio zip: 44109 country: United States lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06305247 id: CLIN-01194-450 id: 2023-506228-10-00 type: OTHER domain: Ipsen briefTitle: A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours overallStatus: RECRUITING date: 2024-04-03 date: 2028-03-20 date: 2028-03-20 date: 2024-03-12 date: 2024-04-19 name: Ipsen class: INDUSTRY briefSummary: The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours.
In this study, all participants will receive the study drug, which will be taken by mouth (orally). conditions: Melanoma conditions: Head and Neck Squamous Cell Carcinoma conditions: Pancreatic Ductal Adenocarcinoma conditions: Colorectal Cancer conditions: Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Phase I is a dose escalation with backfill in participants with selected MAPKm advanced solid tumours.
nctId: NCT06305234 id: 165-503 briefTitle: A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade) overallStatus: RECRUITING date: 2024-01-20 date: 2033-11-18 date: 2033-11-18 date: 2024-03-12 date: 2024-03-12 name: BioMarin Pharmaceutical class: INDUSTRY briefSummary: This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503. conditions: Phenylketonuria (PKU) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Pegvaliase measure: To evaluate immunologic and inflammatory responses associated with occurrences of measure: Evaluation of immunologic and/or inflammatory responses over time measure: Evaluation of immunologic responses over time sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Tulane University School of Medicine status: RECRUITING city: New Orleans state: Louisiana zip: 70112 country: United States lat: 29.95465 lon: -90.07507 hasResults: False
nctId: NCT06305195 id: 0107766 briefTitle: Potential Correlation Between Heart Rate Variability With Cardiovascular Risk at Different Stages of Metabolic Syndrome overallStatus: RECRUITING date: 2023-08-23 date: 2024-09-01 date: 2026-10-21 date: 2024-03-12 date: 2024-03-12 name: Alexandria University class: OTHER briefSummary: The study aims to assess the beat-to-beat Heart rate variability (HRV) in different stages of metabolic diseases, including pre-diabetic and diabetic patients, compared to non-diabetic individuals.
Heart rate variability will be compared for some antidiabetic drugs used in different stages of metabolic diseases and correlated to different metabolic and inflammatory mediators. conditions: Diabetes Mellitus studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 155 type: ESTIMATED name: heart rate variability test measure: Beat-to-beat Heart rate variability measure: body mass index measure: Valsalva ratio measure: Stand 30:15 ratio measure: deep breath test interpretation measure: Framingham risk score (FRS) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Alexandria university status: RECRUITING city: Alexandria country: Egypt name: Hala A. Abo El-Hassan, MSc role: CONTACT phone: 02/01114851485 email: hala.aboelhassan@pua.edu.eg name: Noha A. Hamdy, Dr role: CONTACT phone: 02/01005182151 email: noha.alaaeldine@alexu.edu.eg lat: 31.21564 lon: 29.95527 hasResults: False
nctId: NCT06305169 id: 1.4 briefTitle: Measuring the Negative Predictive Value and Specificity of Serum Biomarkers in Gastric Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-06-01 date: 2024-07-01 date: 2024-03-12 date: 2024-03-12 name: Sandwell & West Birmingham Hospitals NHS Trust class: OTHER briefSummary: Atrophic gastritis where the cells of the stomach lining change is the single most important precursor condition for gastric cancer. Helicobacter pylori a bacteria which causes infection in the stomach is the most important causative agent of inflammation of the stomach, and subsequent atrophic gastritis.
A real word study is needed assess the performance of this blood test in a group of patients referred via an urgent cancer pathway for endoscopy in the UK. Scoring systems have been created to help us triage referrals to endoscopy in those with difficulty swallowing, but no similar score is available for those presenting with other upper abdominal symptoms. By using this blood test as well as collecting patient information we hope to create an improved referral criteria for those needing investigation for gastric cancer. conditions: Gastric Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 440 type: ESTIMATED name: Gastropanel measure: Measurement of the specificity and negative predictive value of serum biomarkers in gastric cancer measure: Creating a scoring system for patients that warrant urgent endoscopy on the cancer pathway sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sandwell General Hospital city: Birmingham state: West Midlands zip: B71 4HJ country: United Kingdom lat: 52.48142 lon: -1.89983 hasResults: False
nctId: NCT06305156 id: CT_BMD_1 briefTitle: Protocol Optimization in CT for the Quantification of BMD overallStatus: RECRUITING date: 2024-03-13 date: 2025-03 date: 2025-03 date: 2024-03-12 date: 2024-03-20 name: Hatem Alkadhi class: OTHER briefSummary: Bone mineral density is an important measurement to detect osteoporosis.
* Study related DXA scan on a separate appointment conditions: Osteoporosis, Osteopenia conditions: Bone Loss studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 150 type: ESTIMATED name: Bone Mineral Density quantification measure: Bone mineral density CT measure: Bone mineral density Dual-energy x-ray absorptiometry (DXA) measure: Correlation between age and bone mineral density measure: Correlation between sex and bone mineral density measure: Correlation between height and bone mineral density measure: Correlation between weight and bone mineral density measure: Correlation between body mass index (BMI) and bone mineral density sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Diagnostic and Interventional Radiology, University Hospital Zurich status: RECRUITING city: Zürich zip: 8091 country: Switzerland name: Hatem Alkadhi, MD, MPH role: CONTACT phone: +41 44 255 36 62 email: hatem.alkadhi@usz.ch lat: 47.36667 lon: 8.54999 hasResults: False
nctId: NCT06305143 id: YFZXYDK202402 briefTitle: Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy overallStatus: RECRUITING date: 2024-04-01 date: 2024-12-31 date: 2025-07-01 date: 2024-03-12 date: 2024-03-12 name: Shanghai Eye Disease Prevention and Treatment Center class: OTHER name: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine briefSummary: The goal of this prospective multicenter open label study is to evaluate the efficacy and safety of intravitreal injection Conbercept (IVC) for the treatment of diabetic macular edema (DME) combined with severe nonproliferative diabetes retinopathy (sNPDR).
* complications and adverse effects conditions: Diabetic Macular Edema studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 58 type: ESTIMATED name: Conbercept measure: improvement of visual acuity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Eye Diseases Prevention &Treatment Center status: RECRUITING city: Shanghai state: Shanghai zip: 201103 country: China name: Tao Sun role: CONTACT phone: +8618916576690 email: drsuntao@yeah.net lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06305130 id: KMUHIRB-E(I)-20180214 briefTitle: Prognostic Value of Performance Scores in Patients Undergoing Surgery for Upper Tract Urothelial Carcinoma overallStatus: COMPLETED date: 1988-01-01 date: 2023-12-31 date: 2023-12-31 date: 2024-03-12 date: 2024-03-12 name: Kaohsiung Medical University class: OTHER briefSummary: Aim: to comprehensively evaluate the prognostic value of preoperative ECOG-PS scores and ASA scores in patients undergoing radical nephroureterectomy (RNU) for upper tract urothelial carcinoma.
Methods: multicentered cohort study conditions: Carcinoma, Transitional Cell (RENI) studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 2515 type: ACTUAL name: No intervention measure: Overall survival measure: Cancer-specific survival measure: Disease-free survival measure: Bladder recurrence-free survival measure: Number of patients with major postoperative complication measure: Number of patients with postoperative renal failure sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06305117 id: PP202304-37-1 id: 101227 type: OTHER_GRANT domain: Association Ruban Rose briefTitle: Virtual RealiTy and mUsic in the Oncology SEtting - Phase 1 acronym: VRtuose1 overallStatus: NOT_YET_RECRUITING date: 2024-10 date: 2025-05 date: 2025-05 date: 2024-03-12 date: 2024-03-12 name: International Agency for Research on Cancer class: OTHER name: Centre Leon Berard briefSummary: The VRtuose (Virtual RealiTy and mUsic in the Oncology Setting) project aims to evaluate the feasibility of implementing in day patient chemotherapy units a distraction strategy combining virtual reality (VR) and music which fits the needs of both breast cancer patients and healthcare providers (i.e., strategy administrators), and to evaluate its impact on patients' (i) perceived anxiety and pain during chemotherapy sessions, (ii) nausea/vomiting and mood disturbances in between chemotherapy sessions, and (iii) quality of life.
In the case that implementation of a distraction strategy combining virtual reality and music to improve quality of life of breast cancer patients during chemotherapy is deemed feasible, the efficacy of using this strategy to improve patients' experience of chemotherapy and long-term quality of life will be evaluated in a future randomized controlled trial informed and optimized by the results of the present work. conditions: Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 60 type: ESTIMATED name: Distraction strategy measure: Patients' acceptance rate regarding the use of the distraction strategy. measure: Accessibility of the strategy measure: Duration of use of the strategy by patients measure: Type of video content chosen by participants measure: Type of music content chosen by participants measure: Patients' perception of factors limiting the use of the strategy measure: Healthcare providers' perception of factors limiting the use of the strategy measure: Workload for strategy administrators measure: Strategy administrators ability to use the strategy measure: Patients' satisfaction regarding the use of the strategy measure: Healthcare providers' satisfaction regarding the strategy measure: Prevalence of adverse events related to the use of the strategy measure: Type of adverse events related to the use of the strategy measure: Severity of adverse events related to the use of the strategy measure: Acceptance rate to fill in questionnaires measuring clinical outcomes measure: Time taken to fill in questionnaires measuring clinical outcomes measure: Completeness of questionnaires measuring clinical outcomes sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Léon Bérard city: Lyon country: France name: Olivier Trédan, MD role: CONTACT email: olivier.tredan@lyon.unicancer.fr name: Olivier Trédan, MD role: PRINCIPAL_INVESTIGATOR lat: 45.74848 lon: 4.84669 hasResults: False
nctId: NCT06305104 id: KN-EEC-II briefTitle: Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old. overallStatus: RECRUITING date: 2023-07-18 date: 2024-05-30 date: 2024-06-30 date: 2024-03-12 date: 2024-03-12 name: Chengdu CoenBiotech Co., Ltd class: INDUSTRY name: Beijing Chest Hospital, Capital Medical University name: Wuhan Institute for Tuberculosis Control name: The Public Health Clinical Center of Chengdu name: Xuzhou Infectious Disease Hospital name: Jiangsu Province Centers for Disease Control and Prevention name: Changde First People's Hospital briefSummary: This is a randomized, blind, positive-controlled study to explore the skin test dosage of recombinant mycobacterium tuberculosis fusion protein ( EEC) in the population aged 18 to 65 years old , and to further evaluate the safety and preliminary efficacy of EEC in the population aged 3 to 75 years old.
In the first stage,180 healthy subjects, 140 tuberculosis（TB）subjects and 40 non-TB subjects with lung diseases aged 18 to 65 years old are divided into different groups through a randomized, blind methods. Every group carry out a low-dose (2.5μg/ml) or high-dose (5μg/ml) study, with 180 subjects in each dose group .Every subject injects intradermally EEC and EC randomly in both arms of the same person. Evaluate the consistency of assay results of EEC, EC and Interferon-Gamma Release Assay（IGRA）.Evaluate the sensitivity, specificity and consistency of assay results of EEC, EC and IGRA in healthy people, TB patients and non-TB patients with lung diseases, and determine the optimal dose of EEC for clinical auxiliary diagnosis of tuberculosis.